File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Treatment outcome and long-term health deficits of patients with low-grade glioma diagnosed during the first year of life

TitleTreatment outcome and long-term health deficits of patients with low-grade glioma diagnosed during the first year of life
Authors
Keywordscerebrovascular disorders
endocrine system diseases
chemotherapy regimen
adjuvant chemotherapy
hypothalamus
Issue Date2018
PublisherOxford University Press. The Journal's web site is located at http://neuro-oncology.dukejournals.org
Citation
The 18th International Symposium on Pediatric Neuro-Oncology (ISPNO 2018) , Denver, Colorado, USA, 30 June – 3 July 2018. Abstracts in Neuro-Oncology, 2018, v. 20 n. Suppl. 2, p. i109, article no. LGG-22 How to Cite?
AbstractLow-grade glioma (LGG) diagnosed during infancy is associated with unique clinical profile and challenges in management. Morbidities in long-term survivors are not well described. We retrospectively reviewed patients with LGG diagnosed before 12 months of age managed at St. Jude Children’s Research Hospital from 1986-2013. Altogether, 51 patients were identified, 31 were males, 7 had neurofibromatosis. Primary tumor locations were hypothalamic/optic pathway (n=31), cerebral (n=6), brainstem (n=6), cerebellar (n=4), and spinal (n=4); 12 patients experienced metastasis. At diagnosis, 41 patients required active intervention: surgical resection (n=23; 5 with adjuvant chemotherapy), chemotherapy (n=16), radiation (n=1), or chemotherapy and radiation (n=1). Throughout the course of disease, 39/51 patients required chemotherapy (median number of regimens: 2; range, 1-13); 21 required radiation (focal=19; CSI=2); and 41 received tumor-directed surgeries (median number of operations: 2; range, 1-6). Twenty-nine patients had grade I tumors; 6 had grade II tumors, and 6 had tumors that could not be definitively graded. CSF diversion was performed in 31 patients. The mean duration of follow-up was 11.5y (range, 0.16-29.19y). Thirty-five patients experienced progression (median progressions: 2; range, 1-18), and 9 patients died (progression=3, malignant transformation=3, shunt infection=1, leukemia=1, unknown=1). The respective 5-year, 10-year, and 20-year overall-survival rates were 91.6 ± 4%, 86.4 ± 5.2%, and 71.9 ± 8.8%. Adverse health issues were documented in 49/51 patients; common morbidities included hearing impairment (n=15), visual impairment (n=31), neurocognitive deficit (n=31), hemiplegia/paraplegia (n=19), endocrinopathy (n=31), and cerebrovascular disease (n=15). LGG diagnosed during infancy was almost universally associated with long-term morbidities and survivors should be prioritized for multi-disciplinary surveillance.
Descriptionposter presentation
Persistent Identifierhttp://hdl.handle.net/10722/265185
ISSN
2020 Impact Factor: 12.3
2020 SCImago Journal Rankings: 4.005

 

DC FieldValueLanguage
dc.contributor.authorLiu, APY-
dc.contributor.authorHastings, C-
dc.contributor.authorWu, S-
dc.contributor.authorBass, JK-
dc.contributor.authorHeitzer, A-
dc.contributor.authorAshford, J-
dc.contributor.authorVestal, R-
dc.contributor.authorHoehn, M-
dc.contributor.authorChiang, J-
dc.contributor.authorGhazwani, Y-
dc.contributor.authorAcharya, S-
dc.contributor.authorConklin, H-
dc.contributor.authorBoop, F-
dc.contributor.authorGajjar, A-
dc.contributor.authorQaddoumi, I-
dc.date.accessioned2018-11-20T02:01:47Z-
dc.date.available2018-11-20T02:01:47Z-
dc.date.issued2018-
dc.identifier.citationThe 18th International Symposium on Pediatric Neuro-Oncology (ISPNO 2018) , Denver, Colorado, USA, 30 June – 3 July 2018. Abstracts in Neuro-Oncology, 2018, v. 20 n. Suppl. 2, p. i109, article no. LGG-22-
dc.identifier.issn1522-8517-
dc.identifier.urihttp://hdl.handle.net/10722/265185-
dc.descriptionposter presentation-
dc.description.abstractLow-grade glioma (LGG) diagnosed during infancy is associated with unique clinical profile and challenges in management. Morbidities in long-term survivors are not well described. We retrospectively reviewed patients with LGG diagnosed before 12 months of age managed at St. Jude Children’s Research Hospital from 1986-2013. Altogether, 51 patients were identified, 31 were males, 7 had neurofibromatosis. Primary tumor locations were hypothalamic/optic pathway (n=31), cerebral (n=6), brainstem (n=6), cerebellar (n=4), and spinal (n=4); 12 patients experienced metastasis. At diagnosis, 41 patients required active intervention: surgical resection (n=23; 5 with adjuvant chemotherapy), chemotherapy (n=16), radiation (n=1), or chemotherapy and radiation (n=1). Throughout the course of disease, 39/51 patients required chemotherapy (median number of regimens: 2; range, 1-13); 21 required radiation (focal=19; CSI=2); and 41 received tumor-directed surgeries (median number of operations: 2; range, 1-6). Twenty-nine patients had grade I tumors; 6 had grade II tumors, and 6 had tumors that could not be definitively graded. CSF diversion was performed in 31 patients. The mean duration of follow-up was 11.5y (range, 0.16-29.19y). Thirty-five patients experienced progression (median progressions: 2; range, 1-18), and 9 patients died (progression=3, malignant transformation=3, shunt infection=1, leukemia=1, unknown=1). The respective 5-year, 10-year, and 20-year overall-survival rates were 91.6 ± 4%, 86.4 ± 5.2%, and 71.9 ± 8.8%. Adverse health issues were documented in 49/51 patients; common morbidities included hearing impairment (n=15), visual impairment (n=31), neurocognitive deficit (n=31), hemiplegia/paraplegia (n=19), endocrinopathy (n=31), and cerebrovascular disease (n=15). LGG diagnosed during infancy was almost universally associated with long-term morbidities and survivors should be prioritized for multi-disciplinary surveillance.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://neuro-oncology.dukejournals.org-
dc.relation.ispartofNeuro-Oncology-
dc.relation.ispartofThe 18th International Symposium on Pediatric Neuro-Oncology (ISPNO 2018)-
dc.subjectcerebrovascular disorders-
dc.subjectendocrine system diseases-
dc.subjectchemotherapy regimen-
dc.subjectadjuvant chemotherapy-
dc.subjecthypothalamus-
dc.titleTreatment outcome and long-term health deficits of patients with low-grade glioma diagnosed during the first year of life-
dc.typeConference_Paper-
dc.identifier.emailLiu, APY: apyliu@hku.hk-
dc.identifier.authorityLiu, APY=rp01357-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/neuonc/noy059.363-
dc.identifier.hkuros295915-
dc.identifier.hkuros315019-
dc.identifier.volume20-
dc.identifier.issueSuppl. 2-
dc.identifier.spagei109-
dc.identifier.epagei109-
dc.publisher.placeUnited States-
dc.identifier.issnl1522-8517-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats